WO1992010202A1 - Proteoglycane(g 009) servant efficacement a ameliorer l'immunite antitumorale - Google Patents
Proteoglycane(g 009) servant efficacement a ameliorer l'immunite antitumorale Download PDFInfo
- Publication number
- WO1992010202A1 WO1992010202A1 PCT/KR1991/000031 KR9100031W WO9210202A1 WO 1992010202 A1 WO1992010202 A1 WO 1992010202A1 KR 9100031 W KR9100031 W KR 9100031W WO 9210202 A1 WO9210202 A1 WO 9210202A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substitute sheet
- effect
- cells
- mouse
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- FIG. 1 is a chromatogram of the sugar analysis of the protein polysaccharide G 009 of the present invention.
- FIG. 2 shows an amino acid chromatogram of the protein polysaccharide G 009 of the present invention.
- FIG. 3 is a micrograph of the mycelium of the strain IY009 of the present invention.
- the present invention relates to a protein polysaccharide having an antitumor / immune enhancing effect.
- the present inventors collected a large number of basidiomycetes in each region for the purpose of searching for a new anti-inflammation and protein polysaccharide having an immunopotentiating effect, and examined the protein polysaccharide produced by the basidiomycetes. Trial of split-building. As a result, when the basidiomycetes belonging to the genus Ganoderma collected at the head of the head of the island, Haenam-gun, Jeollanam-do, were cultured in an appropriate medium, a protein polysaccharide having an anti-inflammatory and immune-enhancing effect was produced. That was discovered. The produced protein polysaccharide was isolated and its physicochemical properties and biological properties were examined. 2.
- SUBSTITUTE SHEET This was named protein polysaccharide G 009 having an antitumor and immunopotentiating effect, and the strain producing it was named Ganodenore manoresida (Ganoderina uuci. In) IY 009.
- This Ganoderma lucidum IY 009 strain was deposited with the Japan National Association of Japan on 5/22/1990 under the deposit number KFCC-10709.
- basidiomycetes belonging to higher S. Cholesterol-lowering components, etc.
- the importance of basidiomycetes is increasing as they are being actively promoted.
- the present inventors are isolating a strain that secretes an anticancer component and a substance having an immune function-enhancing effect, culturing it in a liquid, and studying its pharmacological effects. It is difficult to isolate a variant strain having more excellent anticancer effect and immunopotentiating effect than the species, establish a method for submerged culture of mycelium, extract from this cultured mycelium, and extract the two-component antibody. Effectiveness and immunity enhancement were confirmed. On the other hand, the present inventors explain the present invention with the following examples and experimental examples.
- MgS0 7. 7H 2 0 0.5g, FeCl z .6H? 0 ] 0eg, HnCi 2 .4H 2 0 7mg , ZnSO-, was 5H 2 0 lOag, 1 ⁇ by adding distilled water to ZnC 2 4 mg,
- Cultivation The stored strain is transplanted to a PDA gradient medium and grown at 25 ⁇ 1 ° C for 7 days.
- the mycelium that has developed is aseptically separated and put into 100 ml of submerged culture medium for 500 days.
- the cells were transferred to a triangular flask and cultured at 25 ⁇ 1 at 18 Orpm for 7 to 7 days until the mycelia formed a mature bacterial mass with a diameter of about 3 to 5 mB.
- the obtained bacterial mass is pulverized for 10 seconds with a fine pulverizer, and then added to a 500-ml triangular flask with a submerged culture medium of lOOml in a volume of 52 (V / V).
- the cells were shake-cultured for 7 minutes at 170 rpm with 1 inch (Vision-Yon Science Co.).
- Dialysis was performed for 3 days using a Visking tube: Sigma, J. S.). Dialysis Concentrate after dialysis, add 3 times ethanol, leave at C for 24 hours, then centrifuge at S000 rpm for 15 minutes to obtain a precipitate r Deionize the precipitate Dissolved in water, centrifuged at 6000 rpm for 15 minutes, concentrated the supernatant, and lyophilized to separate the protein polysaccharide.
- G2 (0.42 g). 800 gU of supernatant remaining after removing G2: 800 ml of ethanol was added again, and the resulting precipitate was dried under reduced pressure to obtain ⁇ 3.
- G i (2.1 g) was dissolved in water, applied to Sephadex G-10C (Sephadex G-100), and eluted with water. Tube, freeze-dried fractions of O.25-33 to obtain G4 (.5 g), and tubing of O.34-44
- G5 (0.3 g) was dried under reduced pressure, and G4 separated was dissolved in water again.
- the activity of the fraction obtained above on flesh-180 was carried out as follows.
- a flesh-180 (Sarcoma) was transplanted at weekly intervals in the abdominal cavity of a 20-25 g ICR male mouse.
- -180) were used as tumor cells for experiments.
- Cells of the -180 breed cultured in the mouse peritoneal cavity for 7 days were taken together with ascites, added with ice-cooled and sterilized saline, and centrifuged at 4000 rpm for 5 minutes to separate cell precipitates.
- the separated cells were washed three times with physiological saline, and then diluted to become 1 ⁇ 10 ′′ glaze cell Zm1.
- This cell suspension O.lmJ was subcutaneously transplanted into the left inguinal region with 0 mice per mouse in a group of 1 mouse. 72 hours after tumor cell transplantation, a continuous 1 G H fraction was purified. A certain protein polysaccharide was administered.
- the control group received physiological saline-
- the treatment group received 20 mg / ks of the protein polysaccharide dissolved in saline at a concentration of 0.1 mJ.
- SUBSTITUTE SHEET The mouse was killed on the 30th day after the tumor cells were transplanted, and the induced solid tumor was excised, the weight was measured, and the average tumor weight was determined to obtain the following formula. The percentage was calculated.
- Meat species -18 cells which were implanted at weekly intervals in the abdominal cavity of 20-25 g of ICR male mice, were used as experimental tumor cells.
- Meat seed cells cultured for EI in the mouse abdominal cavity were combined with ascites, water-cooled, and sterilized: fi salt, 1
- Cormorants was diluted by ing the U10 7 cells Bruno "U after the separated cells were washed 3 times with saline. This cell suspension S solution was used to make 10 mice in a group of mice.] X10 ⁇ cells / 0.1 ml were transplanted into the left groin of the mouse. intramuscular, subcutaneous and intraperitoneal injection 20 B g / kg, 5 times intravenous injection at intervals day administered at 1 OAG / kg, 30 days and administered by saline ⁇ . ⁇ in control group the same way After the lapse of time, the weight of the solid cancer was measured and compared.
- ICR male mice were transplanted and transplanted intraperitoneally at weekly intervals of 20-25 g.
- a subcutaneous injection was made at the 10 junction.
- mice in the treatment group and the control group after injection with saline were 10
- the cells were transplanted with 0.11 microliter of the JSS solution. 24 hours after transplantation every other day
- G 009 was injected intramuscularly at a dose of 20 g / kg 10 times.
- Chest ⁇ Serum was separated using the Tadaku a method for 2-3 weeks of age.
- IgG immunoglobulin G fraction from purified antithymic serum
- mice were given a dose of 0.1B! For 10 days.
- G 009 was one meat type 180 transplantation 1 day Septal E! 20 BS / kg at intervals
- N.R.G.H Normal rabbit globulin »Rice mouse
- Complement uses Guinea pig (Guinea pig) serum and human fresh serum
- sheep erythrocytes were used as erythrocytes, and the antibody was used as anti-sheep hemolysin (Anti sheep-heoJysin).
- GVB solution was used to adjust the total volume to 5B1, and the reaction was performed at 37 for 60 minutes, followed by centrifugation at 2500 ⁇ for 5 minutes.
- G 009 exerts an immunopotentiating effect by activating the function of the complement system, one of the important defense functions of the immune system.
- the spleen ⁇ is removed, their weight is measured, and Lysozyee
- lysozyme The activation of lysozyme was added, and it was related to the immune function.
- mice As a test animal, a group of male mice weighing 20 to 25 g was grouped into 5 mice, and samples were intraperitoneally injected at a concentration of 20 g / kg for 5 days continuously.
- SUBSTITUTE SHEET The spleen grafts were allowed to flow by crushing in a blender together with an ever-cooled balanced salt solution.
- a bottom plate was made. Again, after mixing 1U0 ⁇ l of 1 ⁇ cells of 1) and 1% of sheep red blood cells ⁇ ⁇ 2 of 2) in 0.72 agar, they were poured into a plate and spread evenly.
- G 009 is the whole monument «cell number and haemolytic plaque
- mice are administered 0.2 saline 1 of saline. log Co one log C
- ⁇ Co the content of carbon powder in blood at time
- C carbon powder content in blood at time t.
- SUBSTITUTE SHEET G009 is considered to be involved in the immune response
- the acute toxicity test for G 009 was performed on mice and rat rabbits.
- G 009 is a safe guest with extremely low toxicity.
- the mycelium obtained by centrifuging the submerged culture and converting it into Si
- the mycelium was sonicated for 30 seconds under ice cooling.
- the supernatant is used as an electrophoresis sample.
- the protein in the sample was determined using bovine serum albumin (BSA) as a standard.
- BSA bovine serum albumin
- the gel was dispensed at 25 $ C moderation.
- the developed gel was immersed for 30 minutes in 0.2M ⁇ -solution (pH 6.5). It was replaced three times with a new, simple S-mouth liquid that settled. After adjusting the acidity of the gel after immersion, the coloring solution
- Acetate buffer 100 1) was added, and the color was developed at 37 with 30 minutes.
- Reishi's esterase band is one of the first countries
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91920715A EP0610499B1 (en) | 1990-12-04 | 1991-12-04 | Proteoglycan(g 009) effective in enhancing antitumor immunity |
CA002097820A CA2097820C (en) | 1990-12-04 | 1991-12-04 | Proteoglycan(g009) effective in enhancing antitumor immunity |
AT91920715T ATE217530T1 (de) | 1990-12-04 | 1991-12-04 | Zur steigerung der antitumorimmunität wirksames proteoglykan (g009) |
US08/066,162 US5585467A (en) | 1990-12-04 | 1991-12-04 | Proteoglycan(G009) effective in enhancing antitumor immunity |
DE69133010T DE69133010T2 (de) | 1990-12-04 | 1991-12-04 | Zur steigerung der antitumorimmunität wirksames proteoglykan (g009) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1990/19876 | 1990-12-04 | ||
KR1019900019876A KR920010763B1 (ko) | 1990-12-04 | 1990-12-04 | 항종양 면역증강효과가 있는 단백다당체(g 009) |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992010202A1 true WO1992010202A1 (fr) | 1992-06-25 |
Family
ID=19307027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1991/000031 WO1992010202A1 (fr) | 1990-12-04 | 1991-12-04 | Proteoglycane(g 009) servant efficacement a ameliorer l'immunite antitumorale |
Country Status (9)
Country | Link |
---|---|
US (1) | US5585467A (ja) |
EP (1) | EP0610499B1 (ja) |
JP (1) | JP2583385B2 (ja) |
KR (1) | KR920010763B1 (ja) |
AT (1) | ATE217530T1 (ja) |
AU (2) | AU8952191A (ja) |
CA (1) | CA2097820C (ja) |
DE (1) | DE69133010T2 (ja) |
WO (1) | WO1992010202A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721134A (en) * | 1990-12-04 | 1998-02-24 | Il-Yang Pharmaceutical Co., Ltd. | Ganoderma lucidum KCCM 10045 which produces proteoglycan (G009) having effect of antitumor immunity |
RU2040932C1 (ru) * | 1993-12-17 | 1995-08-09 | Крестьянское хозяйство "Агрофирма Дижа" | Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения |
AU3448899A (en) | 1998-01-24 | 1999-08-09 | Bristol-Myers Squibb Company | Artificial proteoglycans |
RU2358723C1 (ru) * | 2008-01-31 | 2009-06-20 | Андрей Александрович Иващенко | Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения |
CN110651995A (zh) * | 2019-10-16 | 2020-01-07 | 福建省印宝文化发展有限公司 | 一种野生肉灵芝浸泡工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5452796A (en) * | 1977-09-30 | 1979-04-25 | Sato Akihiko | Production of krebshemmende substance |
JPS5775926A (en) * | 1980-10-29 | 1982-05-12 | Teikoku Chem Ind Corp Ltd | Production of antitumor substance |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3886986T2 (de) * | 1987-04-28 | 1994-08-11 | Meiji Milk Prod Co Ltd | Glykoprotein, Verfahren zu dessen Herstellung und dieses als aktiven Bestandteil enthaltendes immunsuppressives Agens. |
-
1990
- 1990-12-04 KR KR1019900019876A patent/KR920010763B1/ko not_active IP Right Cessation
-
1991
- 1991-12-04 US US08/066,162 patent/US5585467A/en not_active Expired - Fee Related
- 1991-12-04 WO PCT/KR1991/000031 patent/WO1992010202A1/ja active IP Right Grant
- 1991-12-04 CA CA002097820A patent/CA2097820C/en not_active Expired - Fee Related
- 1991-12-04 AU AU89521/91A patent/AU8952191A/en not_active Abandoned
- 1991-12-04 JP JP4500087A patent/JP2583385B2/ja not_active Expired - Fee Related
- 1991-12-04 AT AT91920715T patent/ATE217530T1/de not_active IP Right Cessation
- 1991-12-04 EP EP91920715A patent/EP0610499B1/en not_active Expired - Lifetime
- 1991-12-04 DE DE69133010T patent/DE69133010T2/de not_active Expired - Fee Related
-
1997
- 1997-03-04 AU AU15090/97A patent/AU1509097A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5452796A (en) * | 1977-09-30 | 1979-04-25 | Sato Akihiko | Production of krebshemmende substance |
JPS5775926A (en) * | 1980-10-29 | 1982-05-12 | Teikoku Chem Ind Corp Ltd | Production of antitumor substance |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
Also Published As
Publication number | Publication date |
---|---|
KR920010763B1 (ko) | 1992-12-17 |
AU8952191A (en) | 1992-07-08 |
CA2097820A1 (en) | 1992-06-05 |
EP0610499A1 (en) | 1994-08-17 |
CA2097820C (en) | 2000-05-16 |
EP0610499A4 (en) | 1994-07-01 |
EP0610499B1 (en) | 2002-05-15 |
DE69133010T2 (de) | 2002-12-05 |
KR920011511A (ko) | 1992-07-24 |
AU1509097A (en) | 1997-06-05 |
JP2583385B2 (ja) | 1997-02-19 |
ATE217530T1 (de) | 2002-06-15 |
US5585467A (en) | 1996-12-17 |
DE69133010D1 (de) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fujii et al. | Isolation and characterization of a new antitumor polysaccharide, KS-2, extracted from culture mycelia of Lentinus edodes | |
Travassos et al. | Sporothrix schenckii and related species of Ceratocystis | |
Gesheva et al. | Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma | |
Barak et al. | Lectin of Sclerotium rolfsii: its purification and possible function in fungal‐fungal interaction | |
Davies | The isolation of mouse antigens carrying H2-histocompatibility specificity: some preliminary studies | |
GB1565090A (en) | Protein-bound polysaccharides | |
Domer et al. | Modulation of immune responses by surface polysaccharides of Candida albicans | |
GB1572074A (en) | Chemotherapeutic substances and methods of manufacturing same | |
Fallon et al. | Praziquantel‐induced exposure of Schistosoma mansoni alkaline phosphatase: drug‐antibody synergy which acts preferentially against female worms | |
WO1992010202A1 (fr) | Proteoglycane(g 009) servant efficacement a ameliorer l'immunite antitumorale | |
US4663438A (en) | Novel nucleic acid-containing glycoprotein | |
Tiwari et al. | Sclerospora graminicola axenic culture | |
Wyler et al. | Influence of malaria infection on the elaboration of soluble mediators by adherent mononuclear cells | |
CA2097821C (en) | Ganoderma lucidum iy009 which produces proteoglycan(g009) having effect of enhancing antitumor immunity | |
JP2747293B2 (ja) | 細菌感染に対する非特異的防御を刺激するための薬剤 | |
Tarnowski et al. | Influence of genotype of host on regression of solid and ascitic forms of sarcoma 180 and effect of chemotherapy on the solid form | |
YOKOTA et al. | Antitumor effects of β-subunit from egg white ovomucin on xenografted sarcoma-180 cells in mice | |
EP0331821B1 (en) | Antiviral agent | |
KR930002831B1 (ko) | 항종양 면역증강효과가 있는 단백다당체(c 909) | |
YOKOTA et al. | In vitro studies of cytotoxic effect on sarcoma-180 cells of β-subunit from egg white ovomucin | |
KR920008373B1 (ko) | 항종양 면역증강효과가 있는 단백다당체(C 909)를 생성하는 코르디셉스(Crdeyceps sp.) IY 909 | |
KR920008375B1 (ko) | 항종양 면역증강효과가 있는 단백다당체(S 818)를 생성하는 균주 쉬조필럼 콤뮨(Schizophyllum commune) IY 818 | |
US5721134A (en) | Ganoderma lucidum KCCM 10045 which produces proteoglycan (G009) having effect of antitumor immunity | |
KR930002830B1 (ko) | 항종양 면역증강효과가 있는 단백다당체(s 818) | |
CN110327458A (zh) | 自分泌vegfb在t细胞代谢与功能以及肿瘤免疫治疗中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2097820 Country of ref document: CA Ref document number: 1991920715 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08066162 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1991920715 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991920715 Country of ref document: EP |